Hyloris Pharmaceuticals SA
EBR:HYL.BR
5.3 (EUR) • At close February 19, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) EUR.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|
| Revenue
| 10.042 | 2.087 | 2.951 | 3.096 | 0.175 | 0.091 | 0.091 | 0.213 |
| Cost of Revenue
| 0.227 | 0.093 | 0.094 | 0.107 | 0.145 | 0.066 | 0.065 | 0.095 |
| Gross Profit
| 9.815 | 1.994 | 2.857 | 2.989 | 0.03 | 0.025 | 0.026 | 0.118 |
| Gross Profit Ratio
| 0.977 | 0.955 | 0.968 | 0.965 | 0.171 | 0.275 | 0.286 | 0.554 |
| Reseach & Development Expenses
| 10.265 | 14.421 | 10.151 | 5.056 | 3.413 | 4.577 | 4.87 | 2.313 |
| General & Administrative Expenses
| 5.627 | 5.546 | 3.517 | 2.9 | 2.194 | 0.808 | 0.622 | 1.657 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 5.627 | 5.546 | 3.517 | 2.9 | 2.194 | 0.808 | 0.622 | 1.657 |
| Other Expenses
| 1.053 | -1.98 | -0.303 | 5.381 | 0 | -0.086 | 0.003 | 0.013 |
| Operating Expenses
| 16.945 | 17.987 | 13.365 | 13.337 | 5.607 | 5.299 | 5.495 | 3.983 |
| Operating Income
| -7.13 | -15.993 | -10.508 | -10.348 | -5.577 | -5.274 | -5.469 | -3.866 |
| Operating Income Ratio
| -0.71 | -7.663 | -3.561 | -3.342 | -31.869 | -57.956 | -60.099 | -18.15 |
| Total Other Income Expenses Net
| 0.788 | 0.613 | -0.263 | -0.741 | -0.119 | -0.508 | -0.59 | 0.083 |
| Income Before Tax
| -6.342 | -15.38 | -10.766 | -11.282 | -7.145 | -5.782 | -6.059 | -3.783 |
| Income Before Tax Ratio
| -0.632 | -7.369 | -3.648 | -3.644 | -40.829 | -63.538 | -66.582 | -17.761 |
| Income Tax Expense
| -0.081 | 0 | 0.004 | 0.297 | 0.001 | -0.014 | -0.02 | -0.066 |
| Net Income
| -6.342 | -15.38 | -10.77 | -11.579 | -7.146 | -5.768 | -5.791 | -3.717 |
| Net Income Ratio
| -0.632 | -7.369 | -3.65 | -3.74 | -40.834 | -63.385 | -63.637 | -17.451 |
| EPS
| -0.22 | -0.55 | -0.4 | -0.45 | -0.28 | -1.15 | -0.25 | -0.16 |
| EPS Diluted
| -0.22 | -0.55 | -0.4 | -0.45 | -0.28 | -1.15 | -0.25 | -0.16 |
| EBITDA
| -4.848 | -14.98 | -11.433 | -10.781 | -6.173 | -5.264 | -5.626 | -3.57 |
| EBITDA Ratio
| -0.483 | -7.178 | -3.874 | -3.482 | -35.274 | -57.846 | -61.824 | -16.761 |